

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL

OMB Number: 3235-0104

Estimated average burden

hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Lortie Brian</u> <hr/> (Last) (First) (Middle) C/O ENDO INTERNATIONAL PLC MINERVA HOUSE, SIMMONSCOUT ROAD <hr/> (Street) BALLSBRIDGE, L2 0 DUBLIN <hr/> (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 03/01/2015	3. Issuer Name and Ticker or Trading Symbol <u>Endo International plc [ENDP]</u> <hr/> 4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director _____ 10% Owner _____ <input checked="" type="checkbox"/> Officer (give title below) _____ Other (specify below) _____ <p style="text-align: center;"><u>President Branded Pharma</u></p>	5. If Amendment, Date of Original Filed (Month/Day/Year) <hr/> 6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person
---	--	--	--

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares	22,584	D	
2010 Stock Incentive Plan Restricted Stock Units (RSU) ⁽¹⁾	831	D	
2010 Stock Incentive Plan Restricted Stock Units (RSU) ⁽²⁾	1,298	D	
2010 Stock Incentive Plan Restricted Stock Units (RSU) ⁽³⁾	1,275	D	
2010 Stock Incentive Plan Restricted Stock Units (RSU) ⁽⁴⁾	2,617	D	
2010 Stock Incentive Plan Performance Shares (PSU) ⁽⁵⁾	5,191	D	
2010 Stock Incentive Plan Performance Shares (PSU) ⁽⁶⁾	10,027	D	
2010 Stock Incentive Plan Performance Shares (PSU) ⁽⁷⁾	3,403	D	
2010 Stock Incentive Plan Performance Shares (PSU) ⁽⁸⁾	5,234	D	

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
2000 Stock Incentive Plan Stock Options (NQ) ⁽⁹⁾	(9)	07/20/2019	Ordinary Shares	32,521	18.62	D	
2004 Stock Incentive Plan Stock Options (NQ) ⁽¹⁰⁾	(10)	02/19/2020	Ordinary Shares	15,427	20.61	D	
2010 Stock Incentive Plan Stock Options (NQ) ⁽¹¹⁾	(11)	02/23/2021	Ordinary Shares	11,098	33.98	D	
2010 Stock Incentive Plan Stock Options (NQ) ⁽¹²⁾	(12)	02/22/2022	Ordinary Shares	10,945	34.7	D	
2010 Stock Incentive Plan Stock Options (NQ) ⁽¹³⁾	(13)	02/27/2023	Ordinary Shares	8,600	30.8	D	
2010 Stock Incentive Plan Stock Options (NQ) ⁽¹⁴⁾	(14)	02/26/2024	Ordinary Shares	6,341	79.33	D	
2010 Stock Incentive Plan Stock Options (NQ) ⁽¹⁵⁾	(15)	02/24/2022	Ordinary Shares	9,659	85.25	D	

Explanation of Responses:

1. 3,324 restricted stock units were granted to Mr. Lortie on February 22, 2012 under the 2010 Stock Incentive Plan, of which 2,493 are vested as of March 1, 2015 (the date of Mr. Lortie's appointment as an executive officer of the registrant), with the unvested portion vesting 25% annually at each future grant date anniversary through February 22, 2016.

2. 2,596 restricted stock units were granted to Mr. Lortie on February 27, 2013 under the 2010 Stock Incentive Plan, of which 1,298 are vested as of March 1, 2015 with the unvested portion vesting 25% annually at each future grant date anniversary through February 27, 2017.

3. 1,701 restricted stock units were granted to Mr. Lortie on February 26, 2014 under the 2010 Stock Incentive Plan, of which 426 are vested as of March 1, 2015 with the unvested portion vesting 25% annually at each future grant date anniversary through February 26, 2018.

4. These restricted stock units were granted to Mr. Lortie on February 24, 2015 under the 2010 Stock Incentive Plan. They vest 25% annually at each future grant date anniversary through February 24, 2019.
5. These performance share units were granted to Mr. Lortie on March 8, 2013 under the 2010 Stock Incentive Plan and vest on March 1, 2016. The amount of performance share units included in this line represents the target quantity of shares issuable. The exact number of shares issuable will be determined on achievement of certain shareholder return targets over a cumulative 3-year period, as determined by the Board of Directors of Endo International plc. The executive can earn between 0% and 300% of the target shares.
6. These performance share units were granted to Mr. Lortie on July 1, 2013 under the 2010 Stock Incentive Plan and vest on July 1, 2016. The amount of performance share units included in this line represents the target quantity of shares issuable. The exact number of shares issuable will be determined on achievement of certain shareholder return targets over a cumulative 3-year period, as determined by the Board of Directors of Endo International plc. The executive can earn between 0% and 300% of the target shares.
7. These performance share units were granted to Mr. Lortie on February 26, 2014 under the 2010 Stock Incentive Plan and vest on February 26, 2017. The amount of performance share units included in this line represents the target quantity of shares issuable. The exact number of shares issuable will be determined on achievement of certain shareholder return targets over a cumulative 3-year period, as determined by the Board of Directors of Endo International plc. The executive can earn between 0% and 300% of the target shares.
8. These performance share units were granted to Mr. Lortie on February 24, 2015 under the 2010 Stock Incentive Plan and vest on February 24, 2018. The amount of performance share units included in this line represents the target quantity of shares issuable. The exact number of shares issuable will be determined on achievement of certain shareholder return targets over a cumulative 3-year period, as determined by the Board of Directors of Endo International plc. The executive can earn between 0% and 300% of the target shares.
9. These non-qualified stock options were granted to Mr. Lortie on July 20, 2009 under the 2000 Stock Incentive Plan, and are fully vested as of March 1, 2015.
10. These non-qualified stock options were granted to Mr. Lortie on February 19, 2010 under the 2004 Stock Incentive Plan, and are fully vested as of March 1, 2015.
11. These non-qualified stock options were granted to Mr. Lortie on February 23, 2011 under the 2010 Stock Incentive Plan, and are fully vested as of March 1, 2015.
12. These non-qualified stock options were granted to Mr. Lortie on February 22, 2012 under the 2010 Stock Incentive Plan. As of March 1, 2015, 8,209 were already vested, with the unvested portion vesting 25% per year on each future grant date anniversary through February 22, 2016.
13. These non-qualified stock options were granted to Mr. Lortie on February 27, 2013 under the 2010 Stock Incentive Plan. As of March 1, 2015, 4,300 were already vested, with the unvested portion vesting 25% per year on each future grant date anniversary through February 27, 2017.
14. These non-qualified stock options were granted to Mr. Lortie on February 26, 2014 under the 2010 Stock Incentive Plan. As of March 1, 2015, 1,586 were already vested, with the unvested portion vesting 25% per year on each future grant date anniversary through February 26, 2018.
15. These non-qualified stock options were granted to Mr. Lortie on February 24, 2015 under the 2010 Stock Incentive Plan. These stock options vest 25% per year on each grant date anniversary through February 24, 2019.

Remarks:

Effective March 1, 2015, Mr. Lortie was appointed as an executive officer of the registrant by its Board of Directors. Mr. Lortie is President, Branded Pharmaceuticals. These securities represent the amounts owned by Mr. Lortie as of March 1, 2015, the date of his appointment.

/s/ Caroline B. Manogue, by 03/06/2015
power of attorney

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

LIMITED POWER OF ATTORNEY FOR
SECTION 16 REPORTING OBLIGATIONS

Know all by these present that the undersigned hereby makes, constitutes and appoints Caroline B. Manogue, Daniel A. Rudio, Dan McCall and Justin Dailey as the undersigned's true and lawful attorneys-in-fact, with full power and authority as hereinafter described on behalf of and in the name, place and stead of each of the undersigned to:

- (1) prepare, execute, acknowledge, deliver and file Forms 3, 4, and 5 (including any amendments thereto) with respect to the securities of Endo International plc, an Irish public limited company (the "Company"), with the United States Securities and Exchange Commission, any national securities exchanges and the Company, as considered necessary or advisable under Section 16(a) of the Securities Exchange Act of 1934 and the rules and regulations promulgated thereunder, as amended from time to time (the "Exchange Act");
- (2) seek or obtain, as the undersigned's representative and on the undersigned's behalf, information on transactions in the Company's securities from any third party, including brokers, employee benefit plan administrators and trustees, and the undersigned hereby authorizes any such person to release any such information to the undersigned and approves and ratifies any such release of information; and
- (3) perform any and all other acts which in the discretion of such attorney-in-fact are necessary or desirable for and on behalf of the undersigned in connection with the foregoing.

The undersigned acknowledges that:

- (1) this Power of Attorney authorizes, but does not require, such attorney-in-fact to act in their discretion on information provided to such attorney-in-fact without independent verification of such information;
- (2) any documents prepared and/or executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney will be in such form and will contain such information and disclosure as such attorney-in-fact, in his or her discretion, deems necessary or desirable;
- (3) neither the Company nor such attorney-in-fact assumes (i) any liability for the undersigned's responsibility to comply with the requirement of the Exchange Act, (ii) any liability of the undersigned for any failure to comply with such requirements, or (iii) any obligation or liability of the undersigned for profit disgorgement under Section 16(b) of the Exchange Act; and
- (4) this Power of Attorney does not relieve the undersigned from responsibility for compliance with the undersigned's obligations under the Exchange Act, including without limitation the reporting requirements under Section 16 of the Exchange Act.

The undersigned hereby gives and grants the foregoing attorney-in-fact full power and authority to do and perform all and every act and thing whatsoever requisite, necessary or appropriate to be done in and about the foregoing matters as fully to all intents and purposes as the undersigned might or could do if present, hereby ratifying all that such attorney-in-fact of, for and on behalf of the undersigned, shall lawfully do or cause to be done by virtue of this Limited Power of Attorney.

This Power of Attorney shall remain in full force and effect with respect to each undersigned until revoked by such undersigned in a signed writing delivered to such attorney-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 3rd day of March 2015.

SIGNATURE

TITLE

/s/ Brian A Lortie
NAME: Brian A Lortie

President, Branded Pharmaceuticals

STATE OF Pennsylvania:
COUNTY OF Chester:

On this 3rd day of March 2015, the above-named individual personally appeared before me, and acknowledged that he executed the foregoing instrument for the purposes therein contained.

IN WITNESS WHEREOF, I have hereunto set my hand and official seal.

/s/ Lynn Marie Iannucci
Notary Public
Chadds Ford TWP., Delaware County
Commission Expires May 11, 2015